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PolyphenolsCumulative evidence now suggests that the abnormal aggregation of the protein α-synuclein (αS) is a critical
factor in triggering neurodegeneration in Parkinson's disease (PD). In particular, a fundamental pathogenetic
mechanism appears to involve targeting of neuronal membranes by soluble oligomeric intermediates of αS,
leading to their disruption or permeabilisation. Therefore, a model assay was developed in which
ﬂuorophore-loaded unilamellar vesicles were permeabilised by soluble oligomers, the latter formed by ag-
gregation of human recombinant αS protein. The αS oligomers induced an impairment of membrane integ-
rity similar to that of the pore-forming bacterial peptide gramicidin. The lipid vesicle permeabilisation assay
was then utilised to screen 11 natural polyphenolic compounds, 8 synthetic N′-benzylidene-benzohydrazide
compounds and black tea extract for protection against membrane damage by wild-type and mutant (A30P,
A53T) synuclein aggregates. A select group of potent inhibitory compounds included apigenin, baicalein,
morin, nordihydroguaiaretic acid, and black tea extract. Structure–activity analysis further suggests that a
5,7-dihydroxy-chromen-4-one moiety appears to be favourable for the inhibition reaction. In conclusion,
we have identiﬁed a group of polyphenols that can effectively hinder membrane damage by αS aggregates.
These may serve as a viable source of lead compounds for the development and design of novel therapeutic
agents in PD.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alpha-synuclein (αS) is a 14.5 kDa, highly-conserved, neuronal pro-
tein that is widely distributed throughout the brain and expressed pre-
dominantly in pre-synaptic terminals [1–4]. Increased expression of αS
and pathologically altered forms of this protein have been implicated in
the pathophysiology of both familial and sporadic Parkinson's disease
(PD), culminating in a loss of nigrostriatal dopaminergic neurons [5].icroscopy; Api, apigenin; Baic,
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l rights reserved.PD is the most common movement disorder and affects approximately
1% of the population over the age of 50with classical clinical manifesta-
tions of bradykinesia, muscle rigidity, resting tremor and postural insta-
bility [6].
The role of the various physical forms (i.e. monomers, soluble olig-
omers, protoﬁbrils or ﬁbrils) of αS in PD pathogenesis remains con-
troversial. Deposits of high-molecular-weight, ﬁbrillar αS aggregates
in neurons, termed Lewy bodies, are a ubiquitous pathological feature
of PD [7]. Substantial data from in vitro and in vivo studies, however,
supports the hypothesis that soluble αS oligomeric intermediates
represent the principal pathogenic species [8–10]. It has been
shown that αS oligomers share a common structure with other
amyloidogenic proteins, such as amyloid-beta, amylin, insulin, and
the cellular prion protein, implying a common mechanism of patho-
genesis [11]. Particularly, there is increasing evidence that these olig-
omers target biological membranes, possibly forming structures with
pore-like morphologies that contribute to cytotoxicity in neurode-
generative diseases via the disruption of cellular and organelle mem-
branes [12–14]. Lipid-bound oligomers of αS were isolated from
brains of transgenic mice as well as from PD patients [15].
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membranes is complex [16,17] and dependent on the phospholipid
composition of the membranes, the size of the vesicles, as well as
the ratio of membrane lipids to protein [18,19]. Thus,αS binds prefer-
entially to small unilamellar vesicles (SUVs) containing acidic
phospholipids such as phosphatidic acid, phosphatidylserine and
phosphatidylglycerol but less strongly to vesicles with a net neutral
charge such as phosphotidylcholine and phosphatidylethanolamine
[20,21]. Only the positively-charged N-terminal and hydrophobic cen-
tral parts of αS (residues 9–90) partake in lipid binding [22] whilst the
negatively charged C-terminal region has been proposed to act as a scaf-
fold to recruit additional proteins to the membranes [23].
Oligomeric αS has been observed to induce bilayer disruption
upon tight binding to membranes containing anionic lipids [24,25].
The leakage of vesicular contents caused by αS oligomers showed a
strong preference for low-molecular-mass molecules, implying a
pore-like mechanism for permeabilisation; monomeric αS was deter-
mined to be less pore forming [24]. In support of these observations,
soluble αS oligomers, but not monomers or ﬁbrils, were able to form
pores in planar lipid bilayers [26]. In cellular models, increased calci-
um inﬂux has been reported using preformed aggregates of αS incu-
bated with Fe3+ and organic solvent [27]. Expression of mutant αS
(Ala30Pro [A30P] and Ala53Thr [A53T]) is associated with a non-
selective ion permeability of the cellular membrane, presumably as
a consequence of relatively large pores [28]. Moreover, both A30P
and A53T mutants have been shown to form pore-like annular and
tubular protoﬁbrillar structures, whilst wild-type (WT) αS formed
annular protoﬁbrils only after extended incubation [29]. Pore forma-
tion may therefore play a role in the pathophysiology of the aggregat-
ed protein by permitting uncontrolled ﬂux of ions into and out of
cells. Aside from pore formation, another mechanistic possibility in-
volves thinning of the plasma membrane [30,31]. Membrane thinning
was directly observed during aggregation of WT and mutant αS on
lipid bilayers; lipid molecules were extracted from the bilayer by
the growing aggregates, ultimately resulting in extensive bilayer dis-
ruption [32]. A recent landmark study reported a direct link between
membrane-bound αS oligomers and severe dopaminergic neuronal
loss in a murine model [33]. The most severe neuronal toxicity corre-
lated with those αS variants that formed oligomers; in turn, the more
toxic oligomerising mutants exhibited a higher afﬁnity to bind lipo-
somes, implying a stronger reactivity to membranes [33]. Hence,
membrane damage by oligomeric αS is considered a likely mecha-
nism of cytotoxicity in PD, which in turn implies that compounds
which interfere with disruption and permeabilisation of membranes
by αS have a potential role in PD.
Currently, no preventive therapy is available for PD [34]. Over the
past decade, intensive research has gone into identifying small organ-
ic molecules that can inhibit and/or disaggregate αS oligomer forma-
tion in vitro [27,35]. Among the most studied are the natural
polyphenolic compounds, characterised by the presence of multiple
hydroxyl groups on aromatic rings [36–40]. Polyphenols either form
soluble, non-toxic, oligomeric complexes with the αS protein or dis-
aggregate mature multimeric structures into smaller, non-toxic ag-
gregates [41–44]. Polyphenols can also interact with and permeate
phospholipid membranes [45]. Both polar and nonpolar forces were
shown to have a signiﬁcant impact on ﬂavonoid–biomembrane inter-
actions [46]. Results of a study in which alterations in membrane
ﬂuidity in a phospholipid bilayer were monitored, suggest that ﬂavo-
noids and isoﬂavonoids, similar to cholesterol and alpha-tocopherol,
partition into the hydrophobic core of the membrane and cause a dra-
matic decrease in lipid ﬂuidity [47].
In summary, it is highly desirable to develop compounds that can
interfere with membrane damage by oligomeric αS since they could
offer powerful therapeutical potential. A liposome permeabilisation
assay, in which synthetic lipid vesicles were exposed to pre-
aggregated αS, was used as a robust screening method to identifysuch compounds. We thereby tested a select group of natural poly-
phenols and N′-benzylidene-benzohydrazide compound derivatives,
that we had previously identiﬁed as potent inhibitors of αS oligomer
formation [27,40].
2. Materials and methods
2.1. Materials
Compounds tested in this work were obtained as follows:
apigenin (Api), baicalein (Baic), black tea extract (BTE; >80%
theaﬂavins), (−)-epigallocatechin gallate (EGCG), genistein (Gen),
ginkgolide B (Gink), morin (Mor), nordihydroguaiaretic acid (NDGA),
propyl gallate (PropylG), purpurogallin trimethyl ether (Purp) and
resveratrol (Resv) were all purchased from Sigma-Aldrich (Munich,
Germany); scutellarein (Scut) was obtained from Pharmasciences Labo-
ratories (Cour-bevoie, France); N′-benzylidene-benzohydrazide (NBB)
compounds were obtained from Chembridge Corp. (San Diego, CA,
USA). In all cases, the purity of the compounds was >98%. Polyphenols,
NBB compounds and BTEwere prepared as stock solutions in DMSO and
stored at−20 °C. During the experiments, compounds were protected
from light and used immediately after thawing. Unless otherwise stated,
all other chemicals indicated in the protocols below were purchased
from Sigma.
2.2. Expression and puriﬁcation of α-synuclein
Wild-type (WT) or mutant (A30P, A53T) human recombinant
αS-containing pET-5a plasmid was transfected into Eschericia coli
BL21 (DE3) cells (Novagen, Madison, WI, USA). Expression was
induced with isopropyl-D-thiogalactopyranose (Promega, Mannheim,
Germany) and theproteins puriﬁed as described previously [48]. Protein
concentration was determined using a bicinchoninic acid protein-
quantiﬁcation kit (Pierce, Rockford, IL, USA). Aliquots of puriﬁed recom-
binant synucleins (0.5–1.0 mg/l) were stored at−80 °C.
2.3. Fluorescent labelling of α-synuclein
Fluorescent labelling of αS with Alexa Fluor-488-O-succinimidylester
(green) and Alexa Fluor-647-O-succinimidylester (red) (Invitrogen,
Eugene, OR, USA) was performed as previously described [27,48]. Quality
control of labelled αS was done by ﬂuorescence correlation spectroscopy
measurements on an Insight Reader (Evotec-Technologies, Hamburg,
Germany). Aliquots of puriﬁed recombinantﬂuorescently-labelledmono-
meric synuclein were stored at−80 °C.
2.4. Preparation of wild-type and mutant α-synuclein aggregates
The aggregation assay was performed as described [48]. Brieﬂy,
7 μM monomeric αS with 1% (v/v) DMSO and 10 μM FeCl3 in sterile
phosphate-buffered saline (PBS) buffer (pH 7.4) was incubated for
4 h at 25 °C. Concentrations given for aggregated αS refer to the re-
spective equivalent monomer concentration.
2.5. Confocal single particle analysis
Fluorescence correlation spectroscopy (FCS), ﬂuorescence intensi-
ty distribution assay (FIDA) and scanning for intensely ﬂuorescent
target (SIFT) measurements were carried out on an Insight Reader
(Evotec-Technologies, Hamburg, Germany) according to established
protocols [48]. In general, ﬂuorescence emitted from dual colour exci-
tation at 488 and 633 nm was recorded simultaneously with two
single-photon detectors. Photons were summed over time intervals
of constant length (bins) using a bin length of 40 μs. The frequency
of speciﬁc combinations of “green” and “red” photon counts, derived
from monomeric control or aggregation measurements respectively,
2504 M. Caruana et al. / Biochimica et Biophysica Acta 1818 (2012) 2502–2510was recorded and presented in two-dimensional intensity distribu-
tion histograms, as shown in Fig. 1A.
2.6. Thioﬂavin T assay
Thioﬂavin T (ThT) is a dye widely used for the detection of cross-
β-sheet structures in proteins, characteristic of the amyloid ﬁbrillar
form. The ThT assay was modiﬁed from an established protocol [49].
Aggregation of αS was monitored over 3 weeks; at each sampling
time, an aliquot of the αS solution was diluted in 12 μM ThT (in
PBS, pH 7.5). Fluorescence was measured in black 96-well plates
using an FLx800-TBID microplate reader (BioTek, Germany), with ex-
citation at 440 nm and emission at 490 nm (slits of 10 nm). To allow
for background ﬂuorescence, the ﬂuorescence intensity of a blank PBS
solution was subtracted from all readings. Data were measured in
triplicates and averaged for evaluations.
2.7. Preparation of SUVs
Vesicles were prepared from a synthetic phospholipid blend
(50 mg/ml, Avanti Polar Lipids, Alabaster, AL, USA) consisting of
1,2-dioleoyl phosphatidylethanolamine (DOPE), 1,2-dioleoyl phos-
phatidylserine (DOPS), 1,2-dioleoyl phosphatidylcholine (DOPC) in
a molar ratio of 5:3:2 (w/w) in chloroform. These vesicles have a
net negative charge and lipid moieties native to the neuronal envi-
ronment [50]. Typically, 50 μg of lipids was thoroughly dried from a
chloroform solution under vacuum, to yield a thin lipid ﬁlm at the
bottom of a glass vial. The thin ﬁlm was hydrated by adding 500 μl
of 100 mM KCl, 10 mM MOPS/Tris, 1 mM EDTA pH 7.0, containing
50 μM Oregon Green® 488 BAPTA-1 (OGB-1; Invitrogen, Darmstadt,
Germany). The suspension was left to hydrate, with vortexing approxi-
mately every 15 min until it turned very cloudy. Subsequently, 60 μl of
0.8 M Mega-9 detergent was added to the suspension, which was thenFig. 1. Aggregation of puriﬁed recombinant wild-type αS. (A) Two-dimensional intensity
distribution histograms obtained in an independent experiment showing the induction
of large oligomers using 1%DMSO and10 μMFe3+ frommonomericαS. TheαS aggregates
are detected as high-intensity signals by SIFT analysis. (B) Fibrillisation kinetics of WT ag-
gregated αS monitored by ThT ﬂuorescence (in arbitrary units, a.u.) compared to control
aggregation buffer only (1% DMSO and 10 μM Fe3+ in sterile PBS, pH 7.4). Sampling of
the αS mix (WT αS) and the aggregation buffer (CTR) was carried out over 21 days. Data
shown as the mean of duplicate measurements (S.E.M. bars b10%).vortexed gently until it appeared clear again. The lipid-solution was
then carefully loaded into Spectra/Por® membrane tubing (pore size,
3.5 kDa; Spectrum Labs, Breda, The Netherlands) and subjected to dial-
ysis for 6 h at 4 °C against a buffer (5 l) containing 100mM KCl,
10 mM MOPS/Tris, pH 7.0. This was followed by two successive over-
night dialyses at 4 °C in the dark, with renewal of fresh buffer each
time. Liposomeswere retrieved from the tubing andkept at 4 °C covered
in aluminium foil. The size and uniformity of the vesicle populationwere
measured using a Zetasizer Nano S dynamic light scattering device
(Malvern, Worcestershire, UK). The vesicles were relatively uniformly-
sized with an average diameter of 65±10 nm (data not shown), and
hence categorised as SUVs.
A similar protocolwas used to prepare calcein-loaded liposomes,with
the following changes: (i) the lipid ﬁlm was resuspended in 500 μl of
50 mM calcein, and (ii) untrapped calcein molecules were removed
using G-25 Sephadex columns (GE Healthcare, Munich, Germany) after
detergent-dialysis.
2.8. Liposome permeabilisation assays
Liposome permeabilisation assays were carried out as described
previously [51], using OGB-1 or calcein as encapsulated ﬂuorophores.
Disruption of liposomes containing OGB-1 causes an increased ﬂuores-
cence (exc. 485 nm, em. 528 nm) as a result of Ca2+ inﬂux and/or OGB-
1 efﬂux. Release of calcein molecules from inside the lipid vesicles
increases ﬂuorescence (exc. 495 nm, em. 520 nm) due to relief of
self-quenching by the dye. Fluorescence measurements were carried
out using an FLx800-TBID microplate reader (BioTek, Germany)
whilst ﬂuorescence intensity data was acquired using KC Junior™ soft-
ware (BioTek, Germany). AggregatedαSwas added to 50 μM liposomes
in assay buffer (1 mM CaCl2, 100 mM KCl, 10 mM MOPS/Tris, 1 mM
EDTA, pH 7.0). Typically, the 5-min values were selected and the per-
centage permeabilisation effect was calculated according to the equa-
tion:
Permeabilisation %ð Þ ¼ 100 F–F0ð Þ= Fmax–F0ð Þ;
where F denotes the ﬂuorescence intensity of the measured sample;
Fmax denotes the maximum ﬂuorescence intensity after the addition of
2 μM ionomycin (a chelating calcium ionophore) in the case of OGB-1 li-
posomes (ca. 6-fold increase), or after the addition of 5%M-PER®mem-
brane detergent (Pierce, Rockford, IL, USA) in the case of calcein
liposomes (ca. 10-fold increase); and F0 represents the ﬂuorescence of
intact vesicles. Fluorescence intensity values are expressed as relative
ﬂuorescence units (RFUs).
2.9. Assays for inhibition of αS-induced liposome permeabilisation
Small-molecule compounds and BTE (typically 50 μM polyphe-
nols, 10 μM NBB compounds and 3 μg/ml BTE) were tested for inhibi-
tion of liposome permeabilisation by two protocols. In protocol A, the
compounds were incubated for 10 min with 50 μM ﬂuorophore-
loaded liposomes, before adding 0.5 μM aggregated αS. In protocol
B, compounds were ﬁrst incubated with aggregated αS for 10 min,
prior to the addition of liposomes. Disruption of lipid vesicles by αS
in the presence of compound was calculated as a percentage of per-
meabilisation caused by αS alone (theoretical maximum, 100%). Au-
toﬂuorescence was measured for each compound and subtracted
from the sample well values. Fluorescence intensity values are given
in RFU.
2.10. Statistical analysis
Statistical analyses were performed using GraphPad™ Prism 5
software (GraphPad Software, Inc.). Unless expressly indicated in
the ﬁgure legend, results were expressed as the means and the
Fig. 2. Lipid vesicle permeabilisation by wild-type αS. The graph in (A) shows per-
meabilisation kinetics upon incubating liposomes with 1% DMSO and 10 μM Fe3+ alone
(Ctr) and with 0.1 μM–0.5 μM pre-aggregated WT αS. Data are representative of at least
3 independent experiments. (B) Concentration-dependence of vesicle permeabilisation
by WT αS oligomers (0.1–1.0 μM), calculated as a percentage of the effect induced by
2 μM ionomycin; 0.5 μM non-aggregated WT αS, representing monomeric αS, is also in-
cluded. Values represent means±S.E.M. (n≥2); ns, not signiﬁcant, compared to 0.8 μM
αS; *pb0.05, compared to 1.0 μM αS; **p=0.001, compared to 0.5 μM oligomeric αS.
(C) Zn2+ and Mg2+ ions (50 and 200 μM) were tested for their effect on liposome per-
meabilisation, after 10 min incubation with pre-aggregated 0.2 μM αS (WT αS). Results
are expressed as a percentage of the leakage induced by WT αS alone (100%; y-axis).
Values represent means±S.D. (n=3); *pb0.05; **pb0.005.
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periments. Differences between means were determined by unpaired
Student's t test. In all analyses, the null hypothesis was rejected at the
0.05 level.
3. Results and discussion
3.1. Generation of wild-type αS oligomers
In several previous studies we have robustly shown that organic
solvent (DMSO) and low micromolar Fe3+ ions trigger in vitro aggre-
gation of monomeric αS into oligomeric species [27,40,48,52]. Oligo-
mers were detected by FIDA and SIFT analysis, indicating formation of
large aggregates of >100meres (Fig. 1A) [27,48]. AFM measurements
conﬁrmed these results and revealed an approximately 100-fold
increase in particle size compared to αS monomers [27]. Characterisa-
tion of the aggregate species by immunoblotting additionally showed
dimers, trimers, tetramers, pentamers and hexamers [48]. The latter is
not unexpected, given the relatively low concentration of αS monomer
(7 μM), the short duration of incubation (4 h) and the temperature
(22 °C). In the present study, we additionally carried out ThT assays to
demonstrate that there was no increase in ﬁbrillar structure of the αS
sample during the ﬁrst 4 h of incubation. Rather, a gradual aggregation
of WT αS into amyloid ﬁbrils occurred over 2–3 weeks, consistent
with a slow nucleation-dependent polymerisation model (Fig. 1B) [53].
3.2. Kinetics of lipid vesicle permeabilisation
The next step involved testing the αS aggregates for their effects
on lipid vesicle integrity. SUVs having a net negative charge and
lipid moieties native to the neuronal environment were prepared
and loaded with OGB-1, a Ca2+-sensitive ﬂuorescent dye, and ex-
posed to various concentrations of preformed WT αS oligomers. En-
hanced ﬂuorescence from Ca2+-bound OGB-1 was monitored for
approximately 30 min; thus, the kinetic measurements reﬂect im-
pairment of vesicle membrane integrity over time. A typical kinetic
recording of the permeabilisation process is shown in Fig. 2A. The
permeabilisation reaction was characterised by a rapid initial phase
(~5 min) followed by a steady, but more gradual, increase in signal
(0.1 and 0.2 μM αS) or saturation (0.5 μM αS). Indeed, aggregated
wild-type αS manifested a clear dose-dependent increase in vesicle
permeabilisation over 0.1–0.8 μM, comparable to that reported in
previous studies (Fig. 2B) [24,54]. It is likely that the increase in per-
meabilisation with higher concentrations of αS oligomers reﬂects a
larger fraction of affected liposomes [54]. Due to a robust (ca. 30%)
and immediate (5 min) liposome disruptive effect with 0.5 μM αS,
this concentration was chosen for most of the subsequent experi-
ments. Of note, 0.5 μM ‘fresh’ (i.e. non-aggregated) αS had a 3-fold
lower permeabilising effect on the vesicles (Fig. 2B). This conﬁrms
the greater membrane afﬁnity of oligomers compared to monomers
[54]. Since Ca2+ ions might artiﬁcially inﬂuence the OGB-1 liposome
permeabilisation assay, calcein-ﬁlled liposomes were also prepared
and exposed to aggregated WT αS. Accordingly, 0.5 μM oligomeric
αS induced a signiﬁcant increase in calcein ﬂuorescence at 5 min
when compared to liposomes alone. In terms of kinetics, the results
obtained were similar to the OGB-1 assays (Fig. 2A and Suppl. Fig. S1).
Therefore, the presence of Ca2+ ions in the OGB-1 assayswas not having
any inﬂuence on the ability of αS oligomers to disrupt vesicular
membranes.
3.3. Membrane perturbation is suggestive of a pore-like mechanism
Two results from the permeabilisation assays point to the likeli-
hood that aggregatedWTαS is relatively efﬁcient at destabilising ves-
icles through a pore-like mechanism, linked to small oligomeric
complexes (trimers to octamers). First, Zn2+ (but not Mg2+) ionsblocked lipid vesicle disruption by aggregated αS by ~60% (Fig. 2C).
Zinc (II) ions have been reported to block non-selective cation chan-
nels formed by αS aggregates in lipid bilayers [55]. Secondly, kinetic
proﬁles of permeabilisation by αS display a striking resemblance to
those of the bacterial pore-forming peptide gramicidin (Fig. 2A and
Suppl. Fig. S2A). In contrast, a detergent-like mechanism would
have resulted in a non-gradual, and immediately complete, per-
meabilisation even at low (b0.5 μM) concentrations of αS (Suppl.
Fig. S2B).
The suggested pore-like mechanism is consistent with a number
of reported studies: Danzer and co-workers similarly used Fe3+ to in-
duce αS oligomers that were cytotoxic and showed pore-like single
Table 1
Inhibitory effect of polyphenols and BTE on WT α-synuclein-induced lipid vesicle
permeabilisation using protocols A and B, and ranking by overall score.
Polyphenols Protocol Aa Protocol Ba Overall
scoreb
Difference of A vs. Bc
(pb0.05)
Mor 23±4%***
(+++)
25±2%***
(+++)
6 ns
BTE 32±7%***
(++)
27±2%***
(+++)
5 ns
Baic 30±5%***
(++)
33±7%***
(++)
4 ns
NDGA 58±1%** (++) 50±5%** (++) 4 ns
Api 77±1%* (+) 31±7%***
(++)
3 More effective in B
EGCG 75±5%* (+) 55±4%** (++) 3 More effective in B
Gen 113±6%ns (−) 44±6%** (++) 2 More effective in B
Scut 81±3%ns (+) 80±5%* (+) 2 ns
PropylG 101±2%ns (−) 77±2%* (+) 1 More effective in B
Resv 99±4%ns (−) 88±4%ns (+) 1 ns
Gink 95±6%ns (−) 93±7%ns (−) 0 ns
Purp 98±4%ns (−) 94±0.3%ns (−) 0 ns
a Eleven polyphenols (50 μM) and BTE (3 μg/ml) were either ﬁrst incubated with 50 μM
OGB-1 liposomes for 10 min, after which WT αS oligomers were included (protocol A), or
were ﬁrst incubated with WT αS oligomers for 10 min, after which 50 μM liposomes were
added (protocol B). In both cases, permeabilisationwasmonitored for 30 min and calculated
as a percentage of the liposome damage caused byαS alone. Potency of each compoundwas
classiﬁed as: no effect (>90%;−);weak effect (60–90%;+);moderate effect (30–59%;++);
strong effect (b30%; +++). Values represent means±S.E.M. (n≥3); *pb0.05; **pb0.005;
***pb0.001.
b The overall score was determined by assigning an arbitrary score of 0–3 points to each
compound, based upon the percentage effectiveness obtained from the twoprotocols utilised
in the study. The best score that can be obtained by a compound is therefore ‘6’.
c Differences between protocols A and Bwere denoted as not signiﬁcant (ns) or signiﬁcant
(pb0.05), if the compound was more effective in either strategy.
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ation of αS ﬁbrils was used to prepare oligomeric αS species, which
also exhibited pore-like characteristics [26].
3.4. Polyphenolic compounds and BTE attenuate lipid vesicle per-
meabilisation by α-synuclein oligomers
The liposome permeabilisation assay was next used to identify
compounds having an inhibitory effect on membrane perturbation
by aggregated WT αS. A total of 11 polyphenols and BTE were
screened for any potential impairment of vesicle membrane integrity
by the compounds themselves. None of the compounds signiﬁcantly
compromised membrane integrity (Suppl. Fig. S3). The inhibitory ef-
fects of polyphenols and BTE on lipid vesicle permeabilisation by ag-
gregated WT αS were then assayed using two protocols A and B, as
outlined in Section 2.9. Brieﬂy, protocol A allows polyphenols and
BTE to ﬁrst interact with the phospholipid membranes of the vesicles,
before exposure to αS. Conversely, protocol B allows for the primary
interaction of the inhibitory compound with the aggregated αS spe-
cies, before including the liposomes andmonitoring permeabilisation.
With regard to protocol B, increasing the incubation time of the com-
pounds with αS aggregates from 10 to 60 min did not alter the inhib-
itory potency of the compounds (data not shown). Results and
comparisons between 11 polyphenols and BTE used in protocols A
and B are given in Table 1. Furthermore, by combining data from
the two protocols (A and B), an overall ‘score’ value was assigned to
each of the 11 polyphenolic compounds and BTE (Table 1). In summa-
ry, these data establish that the compounds with the highest scores,
namely Mor (6/6), BTE (5/6), Baic (4/6) and NDGA (4/6), can be reg-
arded as the best overall in protecting lipid vesicle membranes from
WT αS oligomer-mediated permeabilisation. The polyphenols Mor,
NDGA and BTE were additionally effective at lower concentrations
(Fig. 3A). In order to demonstrate that the observed protective effects
were independent of the permeabilisation assay itself, Baic, Mor and
BTE were also tested on calcein-entrapped liposomes. Indeed, experi-
ments with the calcein-ﬁlled liposomes gave similar results to the
ones obtained using OGB-1-ﬁlled liposomes: Mor, 31%±3 (pb0.005);
BTE, 7%±4 (pb0.005); Baic, 33%±7 (pb0.005).
We have recently published a study in which confocal ﬂuorescence
spectroscopy techniques were used to monitor WT αS aggregation at
the single-molecule level in the presence of naturally-occurring poly-
phenolic compounds and BTE [40]. Correlating the results of these
anti-aggregation assays with those of the liposome permeabilisation
assay above, it is striking to note that BTE, Baic, Mor and NDGA were
all very effective in both assay types. Similarly, compounds having the
lowest scores in the permeabilisation assay, namely Resv, Gink and
Purp, also exhibited the weakest effects in the anti-aggregation assays.
The implication is that the dominant, although not necessarily exclusive,
mechanism involved in protection of lipid vesicles fromαS-inducedper-
meabilisation is in fact destabilisation of the aggregates by the polyphe-
nolic compounds. Exceptions to these observations include Api and Gen,
both of which potently attenuated permeabilisation in protocol Bwhilst
being overallweak in disaggregating activity. Apossiblemechanismhere
might presuppose direct binding of the compounds to soluble αS oligo-
mers, without causing disaggregation of the latter, but still preventing
their interaction with lipid vesicle membranes.
3.5. Polyphenols do not inhibit permeabilisation of liposomes by gramici-
din or detergents
To determine whether the ability of polyphenols to counter mem-
brane destabilisation by αS was a speciﬁc effect against oligomer
permeabilisation, OGB-1-ﬁlled liposomes were exposed to the toxin
gramicidin and Triton X-100 detergent, in the presence of Mor and
BTE. Both polyphenolic compounds did not inhibit vesicle damage by
these two permeabilising agents; by contrast, Mor actually enhancedpermeabilisation by gramicidin (Fig. 3B). Hence, speciﬁc structural fea-
tures, rather than broad biochemical characteristics, likely determine
the inhibitory effect upon synuclein-induced permeabilisation.
3.6. Additive inhibition by pairwise combinations of polyphenols
Taking into consideration the fact that in natural products there is
a heterogeneous mix of polyphenols, we decided to test whether
pairwise combinations of polyphenols would result in an overall en-
hanced, or diminished, biological activity. Thus, NDGA was associated
with 4 other polyphenols in paired combinations: namely BTE (strong
inhibitor), EGCG (moderate inhibitor), PropylG (weak inhibitor) and
Purp (no effect). In each case, the paired combination resulted in an
additive inhibitory effect on liposome permeabilisation by WT αS
(Fig. 3C). In particular, BTE plus NDGA prevented damage to lipid
membranes almost completely (1.6%, pb0.01 when compared to
NDGA alone). Accordingly, at least with these combinations, it ap-
pears that the mechanisms of inhibition by the compounds were in-
dependent and/or overlapping but not conﬂicting.
3.7. Inhibition of αS-induced lipid vesicle permeabilisation by
N′-benzylidene-benzohydrazide derivates
In previous studies, we had identiﬁed several NBB derivates
inhibiting iron-dependent αS oligomer species formation in vitro
[27], as well as in cultured cells [52]. Accordingly, it was of interest
to determine whether this class of synthetic compounds could also
prevent membrane damage by WT αS oligomers. As with the poly-
phenols, NBB compounds were ﬁrst tested for any possible direct
membrane-damaging effects on the synthetic lipid vesicles. None of
the compounds, including the DMSO control, caused any signiﬁcant
liposome disruption (Suppl. Fig. S3). Next, the NBB compounds
were tested using the liposome permeabilisation assay (protocol B
only). Compounds #5 (67%), #7 (84%), and #8 (75%) were found to
be the three most effective compounds. Their chemical structures
Fig. 3. Effect of polyphenols on liposomepermeabilisation byWTαS, gramicidin andmem-
brane detergent. (A) Polyphenols (20–50 μM) and BTE (1–3 μg/ml) were incubated with
50 μMOGB-1 liposomes for 10min, prior to addition of aggregatedWTαS. For each tested
compound, permeabilisation is shown as a percentage of the effect induced by WT αS
alone (100%; x-axis). Values represent means±S.E.M. (n≥2); **pb0.005; ***pb0.001.
(B) Mor (50 μM) and BTE (3 μg/ml) were incubated with 50 μM OGB-1 liposomes for
10 min, after which they were exposed to either 0.05 mg/ml gramicidin (Gram) or 10%
(v/v) Triton X-100 (TrX). Permeabilisation is shown as a percentage of the effect by deter-
gent TrX (100%; y-axis). Values represent means±S.E.M. (n=3). (C) Paired combination
of 20 μMNGDAwith 50 μM BTE, EGCG, PropylG and Purp reveals an additive potentiation
of their inhibitory effect against liposome permeabilisation by WT αS. Values shown here
aremeansof triplicate readings±S.E.M. (n=2); *pb0.05 and **pb0.01 versusNDGA alone.
Fig. 4. Effect of NBB compounds on lipid vesicle permeabilisation by WT αS. 10 μMNBB
compounds (#1–#8) and 10 μM NDGA, were incubated for 10 min with pre-
aggregated WT αS, and 50 μM OGB-1 liposomes added to assess permeabilisation.
Values represent means±S.E.M. (n=2); *pb0.5; **pb0.05; ***pb0.005.
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activity relationships (Section 3.8). With regard to the other NBB
compounds, permeabilisation by WT αS still reached >90%. In direct
comparison, 10 μM NDGA reduced permeabilisation to 49% (Fig. 4).
Recently, we directly evaluated the inﬂuence of the compounds
Baic and NBB #8 on the interaction between αS and model lipid ves-
icles [57]. The synuclein and liposomes were labelled with a different
ﬂuorophore and confocal single-molecule FIDA was performed for
qualitative and quantitative evaluation of the oligomer population
and vesicle integrity. Notably, both these compounds potently dis-
solved membrane-bound, large αS oligomers into monomers, at thesame time leaving the lipid vesicles intact [57]. This ﬁnding conﬁrms
the attractiveness of such compounds for drug development in PD.
3.8. Extension of compound testing to liposome permeabilisation by
mutant αS aggregates
Having established the relative effectiveness of 11 natural polyphe-
nols and 8 NBB compounds in maintaining integrity of membranes
disrupted byWTαS oligomers, we proceeded with testing all the poly-
phenols (incl. BTE) and twoNBB compounds (#5 and #8) againstmem-
brane damage induced by mutant αS aggregates, namely A30P and
A53T αS. The point mutations represent amino acid substitutions in
the α-synuclein gene associated with autosomal-dominant early onset
familial forms of PD, known to accelerate formation of αS oligomers
[58]. Indeed, monitoring of the ﬁbrillisation kinetics of aggregated mu-
tant αS showed that after 7 days both mutants had entered the log-
phase of ﬁbril formation, whilst WT αS reached the log-phase after a
further week of incubation. Importantly, after only 4 h incubation (rep-
resenting the aggregation protocol) mutant and WT αS had very low
ThT ﬂuorescence, implying no cross-β-sheet ﬁbril formation until that
stage (Fig. 5A). Lipid vesicle permeabilisation by 0.5 μM A30P and
A53T aggregates was comparable to that of 0.5 μMWT αS (Fig. 5B).
Inhibition of liposome permeabilisation by the 11 polyphenols
(at 50 μM, except for 20 μM NDGA) was investigated for A30P and
A53T αS, using protocol B. The results are summarised in Table 2,
shown together with the previous data pertaining to WT αS (also
using protocol B). This enabled pooling of all the data for each com-
pound and a ranking table was constructed. In essence, each com-
pound was assigned an arbitrary score of 0–9 points, based upon
its overall effectiveness in inhibiting permeabilisation by the three syn-
ucleins (A30P, A53T,WT). Table 2 shows that NDGA, Api, Gen, Mor, and
BTE can be classiﬁed as the most potent inhibitors, obtaining a high
score of 8 points. A moderate inhibitory effect was manifested by
EGCG (6 points), Baic (5 points), PropylG and Scut (4 points). The
least effective were Purp and Resv (3 points) and Gink (1 point). The
same method was applied to NBB compounds #5 and #8 (at 10 μM),
in direct comparison with NDGA (also at 10 μM). As shown in Table 2,
the polyphenol NDGA compared very favourably to the synthetic com-
pounds (7 points for NDGA and 3 points each for the NBB compounds).
3.9. Structure–activity relationships
An attempt was made to infer potential associations between
chemical scaffolds and compound bioactivity from Table 2 (refer to
Suppl. Fig. S4 for chemical structures of all compounds). Essentially,
the 5,7-dihydroxy-chromen-4-one moiety (found in the ﬂavones
Api, Gen and Mor) appears to be the key pharmacophore favoured
in the inhibition of vesicle permeabilisation (Fig. 6). The other
Fig. 5. (A) Fibrillisation kinetics of mutant αS (A30P, A53T). Aggregation of wild-type
(WT), A30P and A53T α-synuclein was monitored for 3 weeks in a ThT assay (ThT ﬂuo-
rescence, arbitrary units). Shown is the mean of duplicate measurements. (B) Compar-
ison of liposome permeabilisation by mutant (A30P, A53T) and WT aggregated αS.
Permeabilisation of OGB-1 lipid vesicles is given as a percentage of the maximum
ionomycin effect (% ionomycin, y-axis). Values were taken after 5 min permeabilisation
and represent means±S.E.M. (n=4); *pb0.05 compared to WT.
Table 2
Overall polyphenol and N′-benzylidene-benzohydrazide compound scores.
No effect
(>90%)
Mild
(60–90%)
Moderate
(30–59%)
Strong
(b30%)
Overall
score
NDGA (20 μM) WT, 50%** A30P, 28%** 8
A53T, 21%**
Api WT, 31%** A30P, 25%** 8
A53T, 20%**
Gen WT, 44%** A30P, 25%** 8
A53T, 20%**
Mor A53T, 37%** A30P, 18%** 8
WT, 26%**
BTE (3 μg/ml) A53T, 35%** A30P, 28%** 8
WT, 27%**
EGCG A30P, 49%** A53T, 10%** 7
WT, 55%**
Baic A30P, 62%** A53T, 59%** 5
WT, 33.2%**
PropylG WT, 76%* A53T, 47%** 4
A30P, 75%**
Scut A30P, 90%* A53T, 48%** 4
WT, 81%**
Purp WT, 95%ns A30P, 81%** A53T, 44%** 3
Resv A30P, 71%** 3
A53T, 68%*
WT, 63%*
Gink A30P, 104%ns A53T, 86%* 1
WT, 93%ns
NDGA (10 μM) WT, 49%** A53T, 24%** 7
A30P, 38%**
NBB #5 (10 μM) WT, 67%** 3
A30P, 82%**
A53T, 82%**
NBB #8 (10 μM) WT, 75%** 3
A30P, 62%**
A53T, 67%**
Each compoundwas assigned an arbitrary score of 0–3 points, based upon its effectiveness
in inhibiting permeabilisation by the three synucleins (A30P, A53T,WT). Values represent
means±S.E.M. (n≥3); ns = no signiﬁcant difference; *pb0.05; **pb0.005. No effect=0
points; Mild effect=1 point; Moderate effect=2 points; Strong effect=3 points. The
maximum score that can be obtained by a compound is ‘9’ (3+3+3).
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hence a trihydroxylated aromatic ring, in a similar fashion to EGCG
and PropylG. Consequently, trihydroxylated rings appear to be less ef-
fective than dihydroxylated rings for inhibitory activity on per-
meabilisation. Besides, EGCG has a chroman ring structure, which
lacks the carbonyl oxygen on the ‘C’ ring present in the chromene
moiety of the polyphenols Api, Gen and Mor. Interestingly, the sym-
metrical dihydroxylation pattern found in Api, Gen and Mor is also a
feature of NDGA, the only other potent small-molecule compound
which is not a ﬂavonoid. Its compact and symmetrical structure,
with two dihydroxyphenyl rings connected by a rigid linker, may be
particularly suitable for speciﬁc binding to, and destabilisation of, ag-
gregated αS [36,40]. It is particularly revealing that among the NBB
compounds having the best anti-permeabilisation activity, NBB #5,
#7 and #8 all feature an analogous structure to NDGA, with a
dihydroxyphenyl ring at one end of the molecule. Moreover, NBB
#8 (293 G02) has been shown to interfere with αS oligomer forma-
tion in living cells [52].
Black tea is one of the most widely consumed beverages in the
world. Indeed, in a large epidemiological study conducted in Asia,
black tea showed an inverse association with Parkinson's disease
risk that was not confounded by other factors, like total caffeine in-
take or tobacco smoking [59]. It has also been reported that BTE pro-
vided neuroprotection and neurorescue in a neuronal cell model of
PD [60]. These reports are therefore in line with our assay resultsindicating a signiﬁcant effect of BTE in limiting lipid membrane dam-
age by aggregated synucleins.
4. Conclusion
In agreement with others, we conﬁrmed the ability of α-synuclein
oligomers to permeabilise phospholipid membranes, potentially via a
pore-forming mechanism analogous to membrane disruption by bac-
terial toxins [24,55,56,61]. This process of membrane damage could
resemble the mechanism of neuronal toxicity in vivo [62].
In this study, we identiﬁed a group of small-molecule natural poly-
phenols (NDGA, Mor, Baic and Api), as well as black tea extract, that
were found to strongly protect against membrane perturbation
induced by aggregated wild-type and mutant α-synuclein. Our
structure–function comparisons, based upon the polyphenols
and synthetic N′-benzylidene-benzohydrazide derivatives, suggest
that the presence of dihydroxy-phenyl rings, especially within a
5,7-dihydroxy-chromen-4-one scaffold, appears to be favourable
for the inhibition reaction. Indeed, it has been suggested that one
way of improving screening libraries is to include molecules re-
sembling biogenic scaffolds [63]. More detailed investigations into
structure–activity relationships of compounds found in natural
products may guide the design of natural product-inspired mole-
cules with enhanced properties in vivo (e.g. ability to penetrate
blood–brain barrier), but which retain the bioactivity characteristic
of the natural product scaffold. In this respect, it is important to
keep in mind that polyphenols found in human diet are highly
metabolised by microbial enzymes in the colon [64]. These metab-
olites may have a different biological activity from the native
Fig. 6. The 5,7-dihydroxy-chromen-4-one moiety (found in the ﬂavones apigenin,
genistein and morin) appears to be the key pharmacophore favoured in the inhibition
of vesicle permeabilisation by αS.
2509M. Caruana et al. / Biochimica et Biophysica Acta 1818 (2012) 2502–2510substances. Nevertheless, oral administration of polyphenolic com-
pounds has been successful in modulating amyloid aggregation path-
ways and ameliorating neuropathology of various disease models in
vivo. Among these are polyphenols which were found to be particularly
effective in our assays, including NDGA [65], Gen [66], BTE [67], EGCG
[68] and Baic [69]. To conclude, we highlight a promising strategy for
the development of novel lead compounds in Parkinson's disease.
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